Mumbai-headquartered Lupin Limited, one of the leading pharmaceutical drug manufacturer, has informed that the US Food and Drug Administration (FDA) has granted final approval for the company's Abbreviated New Drug Application (ANDA) for Ramipril capsules, 1.25 mg, 2.5 mg, 5 mg and 10 mg.

The commercial shipments of the product have already commenced.

Lupin's Ramipril capsules are the AB-rated generic equivalent of King Pharmaceutical's Altace capsules, indicated for the treatment of hypertension.

According to IMS Health sales data, the brand product had annual sales of about US$920 million for the 12-month period ended December 2007.

The company has posted a net profit of Rs 95.8 crore for the quarter ended March 31, 2008, 32.1 per cent lower than the Rs 141.1 crore net profit posted in the corresponding previous year quarter.